ArticleBMC psychiatry2026
Association between perinatal mood and anxiety disorders treatment status and infant outcomes among privately insured.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo examine the association between maternal perinatal mood and anxiety disorder (PMAD) treatment status and infant outcomes.
methodsWe used a US-based, geographically diverse administrative dataset of commercially insured birthing individuals with newly diagnosed PMAD in the 12-months prior to delivery 2016–2020, with a live linked newborn in Optum’s Clinformatics® Data Mart Database. Our independent variable of interest was evidence of treatment for PMAD diagnosis. Our outcomes of interest were preterm birth (PTB), neonatal intensive care unit (NICU) admission, and neonatal abstinence syndrome (NAS).
resultsTreatment with psychotherapy only was significantly associated with 21% lower odds of PTB compared to no evidence of treatment (aOR: 0.79). Medication-only treatment and combined treatment were not associated with increased risk of PTB. Individuals in the combined treatment group had 24% greater odds of infant NICU admission (aOR: 1.24) compared to those without treatment. Individuals in the medication-only group had 4.18 times the odds of having an infant diagnosed with NAS compared to individuals without treatment (4.4% vs. 1%), while individuals in the combined treatment group had 4.32 times the odds (4.5% vs. 1%), respectively (aOR: 4.18, 4.32).
conclusionsPharmacotherapy use and combination treatments for PMAD may indicate higher disease severity, a risk factor for poor infant outcomes. Discussion of risks associated with pharmacotherapy use must also include a discussion of risks associated with untreated perinatal mental health conditions for birthing individuals and their infants. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.